Chiron Flu Vaccine Reinspection Expected In December
This article was originally published in The Pink Sheet Daily
Executive Summary
House Government Reform Committee Chairman Davis says U.K. health authorities are “very pleased” with Chiron’s progress. The company is more circumspect in discussing prospect of being ready to return to market in 2006.
You may also be interested in...
Chiron Refining GMP Remediation Plan Following FDA Warning Letter
The FDA letter requests additional information on "investigations into cGMP deviations and the design and conduct of studies to aid investigations," Chiron says. The letter follows an inspection of Chiron's Liverpool facility where Fluvirin is produced.
Chiron Refining GMP Remediation Plan Following FDA Warning Letter
The FDA letter requests additional information on "investigations into cGMP deviations and the design and conduct of studies to aid investigations," Chiron says. The letter follows an inspection of Chiron's Liverpool facility where Fluvirin is produced.
Chiron Optimistic About Re-entering U.S. Flu Vaccine Market In 2005
U.K. Medicines & Healthcare Products Regulatory Agency extends suspension of Chiron's license to manufacture Fluvirin by three months, the company says. The extension can be "lifted at any time" once Chiron rectifies the problems at its Liverpool facility, MHRA says.